Q1 2022 Results

Company overview Financial review 2022 priorities Appendix References Strong performance of EntrestoⓇ, KesimptaⓇ, Cosentyx®, ZolgensmaⓇ, Kisqali® and launching LeqvioⓇ... Q1 sales1 Entresto SCAND Kesimpta Sales USD million 1,093 195 Cosenty 1,159 106 zolgensma 363 44 KISQALI 239 44 nbocic Xolair 368 33 LARIS 285 29 PROMAGTA 491 28 ©JAKAVI 389 26 ruppened SCEMBLOX 25 25 MAYZENT 79 24 LEQVIO 14 13 Growth vs. PY USD million 145 Growth vs. PY CC 304 42% nm 12% 18% 28% 17% 18% 9% 14% nm 47% nm Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 35 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY nm not meaningful 1. Innovative Medicines division 6 Investor Relations | Q1 2022 Results 1 GROWTH ✓ NOVARTIS | Reimagining Medicine

View entire presentation